NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Mark Iwicki, Chair

Mark has more than 25 years of biopharmaceutical industry experience. He is the Chairman, President and CEO of Kala Pharmaceuticals and was previously the CEO of Civitas Therapeutics which was acquired by Acorda Therapeutics. Prior to Civitas, Mark served as the President and Chief Executive Officer of Blend Therapeutics and President and Chief Executive Officer of Sunovion Pharmaceuticals. He was President and Chief Operating Officer at Sepracor, which was acquired in 2009, and serves on several boards.